Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes
Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
Beta-blockers are medications used to treat cardiovascular disease (CVD) symptoms, including
high blood pressure and chest pain. People with diabetes who receive beta-blockers may
experience adverse health effects, but the exact cause of why this happens remains unknown.
This study will examine the genetic factors that may influence how atenolol, a beta-blocker
medication, affects fat breakdown, blood sugar levels, and heart function in people with type
2 diabetes.
Phase:
Phase 4
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI) University of Maryland, Baltimore
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) University of Maryland